This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhu, Y. Articles by Duan, W. Search for Related Content PubMed PubMed Citation Articles by Zhu, Y. Articles by Duan, W.

The PKC-D294G Mutant Found in Pituitary and Thyroid Tumors Fails to Transduce Extracellular Signals

Departments of ¹ Biochemistry and ² Pharmacy, Faculty of Science, The National University of Singapore, Singapore, Singapore; and ³ Department of Medicine and Sydney Cancer Centre, University of Sydney, Sydney, Australia

Requests for reprints: Wei Duan, Department of Biochemistry, Faculty of Medicine, The National University of Singapore, 8 Medical Drive, Singapore, 117597. Phone: 65-6874-3688; Fax: 65-6779-1453; E-mail: bchduanw{at}nus.edu.sg.

Protein kinase C (PKC) is a key regulator of cell proliferation, differentiation, and apoptosis and is one of the drug targets of anticancer therapy. Recently, a single point mutation (D294G) in PKC has been found in pituitary and thyroid tumors with more invasive phenotype. Although the PKC-D294G mutant is implicated in the progression of endocrine tumors, no apparent biochemical/cell biological abnormalities underlying tumorigenesis with this mutant have been found. We report here that the PKC-D294G mutant is unable to bind to cellular membranes tightly despite the fact that it translocates to the membrane as efficiently as the wild-type PKC upon treatment of phorbol ester. The impaired membrane binding is associated with this mutant's inability to transduce several antitumorigenic signals as it fails to mediate phorbol ester–stimulated translocation of myristoylated alanine–rich protein kinase C substrate (MARCKS), to activate mitogen-activated protein kinase and to augment melatonin-stimulated neurite outgrowth. Thus, the PKC-D294G is a loss-of-function mutation. We propose that the wild-type PKC may play important antitumorigenic roles in the progression of endocrine tumors. Therefore, developing selective activators instead of inhibitors of PKC might provide effective pharmacological interventions for the treatment of certain endocrine tumors.

This article has been cited by other articles:

				B. Diouf, A. Collazos, G. Labesse, F. Macari, A. Choquet, P. Clair, C. Gauthier-Rouviere, N. C. Guerineau, P. Jay, F. Hollande, et al. A 20-Amino Acid Module of Protein Kinase C{epsilon} Involved in Translocation and Selective Targeting at Cell-Cell Contacts J. Biol. Chem., July 10, 2009; 284(28): 18808 - 18815. [Abstract] [Full Text] [PDF]

				A. Ghoul, M. Serova, L. Astorgues-Xerri, I. Bieche, G. Bousquet, M. Varna, M. Vidaud, E. Phillips, S. Weill, K. A. Benhadji, et al. Epithelial-to-Mesenchymal Transition and Resistance to Ingenol 3-Angelate, a Novel Protein Kinase C Modulator, in Colon Cancer Cells Cancer Res., May 15, 2009; 69(10): 4260 - 4269. [Abstract] [Full Text] [PDF]

				A. A. Hizli, A. R. Black, M. A. Pysz, and J. D. Black Protein Kinase C {alpha} Signaling Inhibits Cyclin D1 Translation in Intestinal Epithelial Cells J. Biol. Chem., May 26, 2006; 281(21): 14596 - 14603. [Abstract] [Full Text] [PDF]